Senator Investment Group LP Purchases New Holdings in Boston Scientific Corporation $BSX

Senator Investment Group LP purchased a new position in shares of Boston Scientific Corporation (NYSE:BSX) in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 300,000 shares of the medical equipment provider’s stock, valued at approximately $12,804,000.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Kelleher Financial Advisors bought a new stake in shares of Boston Scientific in the 2nd quarter valued at approximately $25,000. FWL Investment Management LLC acquired a new stake in shares of Boston Scientific in the 2nd quarter worth about $26,000. Swiss RE Ltd. bought a new stake in shares of Boston Scientific during the fourth quarter valued at approximately $26,000. Garton & Associates Financial Advisors LLC bought a new stake in Boston Scientific during the 4th quarter valued at $26,000. Finally, Clal Insurance Enterprises Holdings Ltd acquired a new stake in Boston Scientific in the first quarter worth about $28,000. 89.07% of the stock is owned by institutional investors.

Insider Transactions at Boston Scientific

In other Boston Scientific news, Director David C. Habiger bought 2,100 shares of the firm’s stock in a transaction dated Wednesday, August 5th. The shares were acquired at an average cost of $47.59 per share, for a total transaction of $99,939.00. Following the transaction, the director owned 17,160 shares in the company, valued at approximately $816,644.40. The trade was a 13.94% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CEO Michael F. Mahoney acquired 186,240 shares of the firm’s stock in a transaction on Monday, August 3rd. The shares were bought at an average cost of $48.33 per share, for a total transaction of $9,000,979.20. Following the completion of the acquisition, the chief executive officer directly owned 1,590,024 shares of the company’s stock, valued at approximately $76,845,859.92. This represents a 13.27% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. In the last three months, insiders acquired 194,522 shares of company stock valued at $9,385,210. Company insiders own 0.34% of the company’s stock.

Boston Scientific Trading Down 0.0%

Shares of BSX stock opened at $46.82 on Monday. The firm’s fifty day simple moving average is $46.56 and its 200 day simple moving average is $56.53. The firm has a market capitalization of $67.85 billion, a P/E ratio of 18.96, a price-to-earnings-growth ratio of 1.02 and a beta of 0.56. The company has a current ratio of 1.24, a quick ratio of 0.74 and a debt-to-equity ratio of 0.43. Boston Scientific Corporation has a 1 year low of $42.20 and a 1 year high of $109.50.

Boston Scientific (NYSE:BSX) last released its earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share for the quarter, beating the consensus estimate of $0.83 by $0.03. Boston Scientific had a net margin of 17.50% and a return on equity of 19.28%. The business had revenue of $5.44 billion during the quarter, compared to analysts’ expectations of $5.38 billion. During the same quarter last year, the company earned $0.75 earnings per share. The firm’s revenue was up 7.5% on a year-over-year basis. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. As a group, sell-side analysts predict that Boston Scientific Corporation will post 3.3 EPS for the current year.

Boston Scientific announced that its board has authorized a stock buyback program on Monday, May 18th that permits the company to buyback $5.00 billion in shares. This buyback authorization permits the medical equipment provider to reacquire up to 6.4% of its shares through open market purchases. Shares buyback programs are typically an indication that the company’s management believes its stock is undervalued.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on the company. Oppenheimer cut their target price on Boston Scientific from $90.00 to $85.00 and set an “outperform” rating for the company in a research report on Monday, July 27th. UBS Group cut their price target on shares of Boston Scientific from $74.00 to $67.00 and set a “buy” rating on the stock in a report on Thursday, July 30th. Deutsche Bank Aktiengesellschaft restated a “buy” rating and set a $60.00 price objective on shares of Boston Scientific in a research report on Thursday, July 30th. Zacks Research cut shares of Boston Scientific from a “hold” rating to a “strong sell” rating in a report on Friday, June 5th. Finally, Argus reissued a “hold” rating on shares of Boston Scientific in a research note on Friday, July 31st. Twenty-four equities research analysts have rated the stock with a Buy rating, five have issued a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat, Boston Scientific currently has a consensus rating of “Moderate Buy” and an average price target of $71.62.

Boston Scientific Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.